4Bihan H,Espinosa C,Valdes-Socin H,et al.Long-term outcome of patients with acromegaly and congestive heart failure.J Clin Endocrinol Metab,2004,89:5308-5313.
5Colao A,Marzullo P,Ferone D,et al.Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.J Clin Endocrinol Metab,2000,85:3132-3140.
6Mutta MP,Caron P.Acromegalic cardiomyopathy:a review of the literature.Pituitary,2003,6:203-207.
7Colao A,Cuocolo A,Marzullo P,et al.Is the acromegallc cardiomyopathy reversible?Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.J Clin Endocrinol Metab,2001,86:1551-1557.
8Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics and Transhtional Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention.Circulation,2006,113:1807-1816.
9Twickler M,Cramer MJ,van Dam PS,et al.Significant improvement of acromegaly-induced cardiomyopathy after normalization of GH levels:case report and review.Endocrinologist,2003,13:3:169-172.
10Merola B,Cittadini A.Colao A,et al.Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.J Clln Endocrinol Metab,1993,77:3:790-793.
